Methylphenidate warnings updated

Prescribing information for methylphenidate is being updated following a review of the drug's safety conducted by the EMEA earlier this year.

The agency concluded that the benefits of medicines containing methylphenidate outweigh their risks when used to treat ADHD in children aged six years and above.

However, prescribing advice for these products has been updated to emphasise the need to screen and monitor for cardiovascular and psychiatric problems before and during treatment.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases